AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
28 Agosto 2024 - 10:00PM
Business Wire
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical
company focused on discovering and developing novel small molecule
therapeutics derived from its boron chemistry platform, today
announced that Eric Easom, Co-Founder, Chairman, President and CEO
will present at the H.C. Wainwright 26th Annual Global Investment
Conference.
Details of the event is as follows:
H.C. Wainwright 26th Annual Global Investment Conference
- Eric Easom, Co-Founder, Chairman, President and CEO will
provide a corporate overview on Tuesday, September 10 at 9:30am
ET
A webcast of the presentation can be accessed on the Investors
section of the AN2 Therapeutics website at www.an2therapeutics.com.
An archived replay will be available for at least 30 days following
the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on
discovering and developing novel small molecule therapeutics
derived from its boron chemistry platform. AN2 has a pipeline of
boron-based compounds in development for Chagas disease,
nontuberculous mycobacteria (NTM), and melioidosis, along with
early-stage programs focused on targets in infectious diseases and
oncology. For more information, please visit our website at
www.an2therapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828371113/en/
COMPANY CONTACT: Lucy O. Day Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT: Anne Bowdidge
ir@an2therapeutics.com
Grafico Azioni AN2 Therapeutics (NASDAQ:ANTX)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni AN2 Therapeutics (NASDAQ:ANTX)
Storico
Da Feb 2024 a Feb 2025
